CalciMedica Inc
CALC2.840USD
-0.100-3.40%
Market hours （ET）Quotes delayed by 15 min
39.68MMarket Cap
LossP/E TTM
More Details of CalciMedica Inc Company
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
Company Info
Ticker SymbolCALC
Company nameCalciMedica Inc
IPO dateSep 25, 2020
CEODr. A. Rachel Leheny, Ph.D.
Number of employees14
Security typeOrdinary Share
Fiscal year-endSep 25
Address505 Coast Boulevard South
CityLA JOLLA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92037
Phone18589525500
Websitehttps://calcimedica.com/
Ticker SymbolCALC
IPO dateSep 25, 2020
CEODr. A. Rachel Leheny, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert N. Wilson
Mr. Robert N. Wilson
Independent Chairman of the Board
Independent Chairman of the Board
422.03K
+1.08%
Mr. Eric W. Roberts
Mr. Eric W. Roberts
Chief Business Officer, Director
Chief Business Officer, Director
238.48K
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Director
Director
90.73K
--
Dr. Sudarshan Hebbar, M.D.
Dr. Sudarshan Hebbar, M.D.
Chief Medical Officer
Chief Medical Officer
46.00K
--
Mr. Stephen Bardin
Mr. Stephen Bardin
Chief Financial Officer
Chief Financial Officer
41.00K
+2.50%
Mr. Fred Middleton
Mr. Fred Middleton
Independent Director
Independent Director
--
--
Ms. Sarah C. Sutton
Ms. Sarah C. Sutton
Investor Relations
Investor Relations
--
--
Dr. Alan Glicklich, M.D.
Dr. Alan Glicklich, M.D.
Independent Director
Independent Director
--
--
Mr. Michael J. Dunn
Mr. Michael J. Dunn
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Allan L. Shaw
Mr. Allan L. Shaw
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert N. Wilson
Mr. Robert N. Wilson
Independent Chairman of the Board
Independent Chairman of the Board
422.03K
+1.08%
Mr. Eric W. Roberts
Mr. Eric W. Roberts
Chief Business Officer, Director
Chief Business Officer, Director
238.48K
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Director
Director
90.73K
--
Dr. Sudarshan Hebbar, M.D.
Dr. Sudarshan Hebbar, M.D.
Chief Medical Officer
Chief Medical Officer
46.00K
--
Mr. Stephen Bardin
Mr. Stephen Bardin
Chief Financial Officer
Chief Financial Officer
41.00K
+2.50%
Mr. Fred Middleton
Mr. Fred Middleton
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sanderling Ventures
17.23%
Deerfield Management Company, L.P.
9.30%
Alafi Capital Company, LLC
9.27%
Soleus Capital Management, L.P.
5.61%
Valence Investments SPV IV LLC
5.29%
Other
53.29%
Shareholders
Shareholders
Proportion
Sanderling Ventures
17.23%
Deerfield Management Company, L.P.
9.30%
Alafi Capital Company, LLC
9.27%
Soleus Capital Management, L.P.
5.61%
Valence Investments SPV IV LLC
5.29%
Other
53.29%
Shareholder Types
Shareholders
Proportion
Venture Capital
26.50%
Hedge Fund
15.75%
Individual Investor
11.33%
Investment Advisor/Hedge Fund
10.54%
Corporation
5.29%
Investment Advisor
5.25%
Research Firm
0.07%
Other
25.26%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
64
10.45M
74.91%
-138.94K
2025Q1
67
10.50M
75.19%
-73.57K
2024Q4
77
9.43M
69.96%
+904.34K
2024Q3
74
8.10M
73.88%
-536.77K
2024Q2
71
7.97M
73.62%
+208.30K
2024Q1
70
7.99M
73.84%
+495.63K
2023Q4
66
4.06M
70.08%
+1.98M
2023Q3
72
4.04M
72.45%
+2.86M
2023Q2
84
4.13M
73.98%
+3.33M
2023Q1
116
3.41M
61.29%
+2.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sanderling Ventures
2.41M
17.23%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
1.30M
9.3%
--
--
Mar 31, 2025
Alafi Capital Company, LLC
1.30M
9.27%
+1.30M
--
Mar 25, 2025
Soleus Capital Management, L.P.
783.90K
5.61%
--
--
Mar 31, 2025
Valence Investments SPV IV LLC
739.33K
5.29%
--
--
Mar 31, 2025
Aisling Capital Management LP
521.11K
3.73%
--
--
Mar 31, 2025
Lytton (Laurence W)
468.94K
3.36%
-25.93K
-5.24%
Sep 30, 2024
Pengana Capital Group Limited
449.00K
3.21%
--
--
Feb 28, 2025
Wilson (Robert N)
417.53K
2.99%
--
--
Mar 31, 2025
Stonepine Capital Management, LLC
367.37K
2.63%
-101.42K
-21.63%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
